Story perspectives

Cytokine Risks and Autoimmunity Impact CAR T Therapy Outcomes

11/13/2025

43 7

Summary

Story summary

In a study of 170 patients with large B-cell lymphoma, higher monocyte-count Polygenic Risk Scores linked to 2.5-fold risk of cytokine release syndrome during Chimeric Antigen Receptor T-cell (CAR T) therapy.
A second study of 1,321 patients in CAR T therapy found autoimmune diseases linked to shorter hospital stays and lower toxicity.
Limitations include retrospective design and small samples, which may limit generalizability and affect interpretation for CAR T trials.

1 of 1

Story summary

In a study of 170 patients with large B-cell lymphoma, higher monocyte-count Polygenic Risk Scores linked to 2.5-fold risk of cytokine release syndrome during Chimeric Antigen Receptor T-cell (CAR T) therapy.
A second study of 1,321 patients in CAR T therapy found autoimmune diseases linked to shorter hospital stays and lower toxicity.
Limitations include retrospective design and small samples, which may limit generalizability and affect interpretation for CAR T trials.